RxDoctor Payments DataLook up a doctor →

Colt Williams, MD

Hematology & Oncology · Reno, NVNPI 1740712108

Payments from drug & device makers

$6,278in general payments, 2019–2025

Across 177 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Daiichi Sankyo Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$362
  • Sanofi$272
  • AbbVie$249
  • AstraZeneca$239
  • plus $2K from 33 others

What the payments were for

  • Consulting fees$70511%
  • Food & beverage$3,45955%
  • Education$2514%
  • Other$1,86330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,278 in reported general payments places this provider in the 30th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada

Medicare billing

Part B allowed, 2024
$2,305,896
Medicare patients
273
Services billed
78,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KeytrudaPembrolizumab34$381,290
LenvimaLenvatinib Mesylate15$356,213
RevlimidLenalidomide21$258,200
JakafiRuxolitinib Phosphate15$255,835
ImfinziDurvalumab19$245,246
VenclextaVenetoclax20$214,566
LibtayoCemiplimab-Rwlc13$129,777
XareltoRivaroxaban16$13,187
Olanzapine69$1,128
Dexamethasone45$701
Ondansetron Hcl47$646
Albuterol Sulfate HfaAlbuterol Sulfate12$518
Hydroxyurea29$426
Prochlorperazine Maleate38$419
Ondansetron OdtOndansetron14$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckKeytruda$105$381,29034 claims
Eisai Inc.Lenvima$62$356,21315 claims
Incyte CorporationJakafi$99$255,83515 claims
AstraZenecaImfinzi$239$245,24619 claims
AbbVieVenclexta$249$214,56620 claims
Regeneron Healthcare Solutions, Inc.Libtayo$137$129,77713 claims
Johnson & JohnsonXarelto$190$13,18716 claims
Lilly USA, LLCOlanzapine$16$1,12869 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 82 hematology & oncology providers in Nevada.

Other hematology & oncology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →